Acta Med. 2019, 62: 123-126

https://doi.org/10.14712/18059694.2019.136

Myelin Oligodendrocyte Glycoprotein Antibody Associated Transverse Myelitis

Iveta Chroustováa, Miroslav Mareša, Leoš Ungermannb,c, Edvard Ehlera,c

aDepartment of Neurology, Pardubice Regional Hospital, Czech Republic
bDepartment of Radiology, Pardubice Regional Hospital, Czech Republic
cFaculty of Health Care Studies, Pardubice University, Czech Republic

Received May 16, 2019
Accepted August 16, 2019

References

1. Jarius S, Paul F, Aktas O, et al. MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing. Journal of Neuroinflammation 2018; 15: 134–44. <https://doi.org/10.1186/s12974-018-1144-2> <PubMed>
2. Zhou Y, Jia X, Yang H,et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Demyelination: Comparison Between Onset Phenotypes 2018; 26: 175–83.
3. Yeh EA, Nakashima I. Live-cell Based Assays Are the Gold Standard for Anti-MOG-Ab Testing. Neurology 2019; 92: 501–2. <https://doi.org/10.1212/WNL.0000000000007254>
4. Han J, Yang M, Zhu J, Jin T. Complexity and Wide Range of Neuromyelitis Optica Spectrum disorders: more than typical manifestations. Neuropsychiatric Disease and Treatment 2017; 13: 2653–60. <https://doi.org/10.2147/NDT.S147360> <PubMed>
5. Jurynchyk M, Messin S, Woodhall MR,et al. Clinical Presentation and Prognosis in MOG-antibody Disease: a UK Study. Brain 2017; 140: 3128–38. <https://doi.org/10.1093/brain/awx276>
6. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults. The MOGADOR study. Neurology 2018; 90: e1858–e1869. <https://doi.org/10.1212/WNL.0000000000005560>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive